These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 1940375)
41. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Pye D; Vandenberg KL; Dyer SL; Irving DO; Goss NH; Woodrow GC; Saul A; Alving CR; Richards RL; Ballou WR; Wu MJ; Skoff K; Anders RF Vaccine; 1997 Jun; 15(9):1017-23. PubMed ID: 9261951 [TBL] [Abstract][Full Text] [Related]
42. Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice. Rafi-Janajreh A; Tongren JE; Kensil C; Hackett C; Candal F; Lal A; Udhayakumar V Exp Parasitol; 2002 May; 101(1):3-12. PubMed ID: 12243733 [TBL] [Abstract][Full Text] [Related]
43. Roles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum. Hui GS; Hashimoto A; Chang SP Infect Immun; 1992 Apr; 60(4):1422-33. PubMed ID: 1548068 [TBL] [Abstract][Full Text] [Related]
44. Plasmodium falciparum: elicitation by peptides and recombinant circumsporozoite proteins of circulating mouse antibodies inhibiting sporozoite invasion of hepatoma cells. Hollingdale MR; Ballou WR; Aley SB; Young JF; Pancake S; Miller LH; Hockmeyer WT Exp Parasitol; 1987 Jun; 63(3):345-51. PubMed ID: 2438152 [TBL] [Abstract][Full Text] [Related]
45. Clonal repertoire analysis of murine B cells specific for repeat sequence antigens of Plasmodium falciparum. Venn AJ; Anders RF; Pike BL; Shortman K Parasite Immunol; 1990 Nov; 12(6):605-21. PubMed ID: 1707507 [TBL] [Abstract][Full Text] [Related]
46. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli. Wirtz RA; Ballou WR; Schneider I; Chedid L; Gross MJ; Young JF; Hollingdale M; Diggs CL; Hockmeyer WT Exp Parasitol; 1987 Apr; 63(2):166-72. PubMed ID: 3552712 [TBL] [Abstract][Full Text] [Related]
47. Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine. Hui G; Hashimoto C Vaccine; 2007 Sep; 25(36):6598-603. PubMed ID: 17688975 [TBL] [Abstract][Full Text] [Related]
48. Reduction of disulfide bonds in Plasmodium falciparum gp195 abolishes the production of growth-inhibitory antibodies. Locher CP; Tam LQ Vaccine; 1993; 11(11):1119-23. PubMed ID: 8249430 [TBL] [Abstract][Full Text] [Related]
49. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Alving CR Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907 [TBL] [Abstract][Full Text] [Related]
50. Immunogenicity and antigenicity of the N-term repeat amino acid sequence of the Plasmodium falciparum P126 antigen. Banic DM; Bossus M; Delplace P; Tartar A; Gras-Masse H; Conseil V; Mazingue C; de Taisne C; Camus D Mem Inst Oswaldo Cruz; 1992; 87 Suppl 3():159-62. PubMed ID: 1343686 [TBL] [Abstract][Full Text] [Related]
51. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Wiley SR; Raman VS; Desbien A; Bailor HR; Bhardwaj R; Shakri AR; Reed SG; Chitnis CE; Carter D Sci Transl Med; 2011 Jul; 3(93):93ra69. PubMed ID: 21795589 [TBL] [Abstract][Full Text] [Related]
52. Intraerythrocytic administration of a synthetic Plasmodium antigen elicits antibody response in mice, without carrier molecules or adjuvants. Esposito F; Santroni AM; Habluetzel A; Grelloni V; Pessi A; Lombardi S; Falcioni G; Brunori M Int J Parasitol; 1990 Dec; 20(8):1109-11. PubMed ID: 2074141 [TBL] [Abstract][Full Text] [Related]
53. A peptide derived from a B cell epitope of Plasmodium falciparum rhoptry associated protein 2 specifically raises antibodies to rhoptry associated protein 1. Stowers AW; Cooper JA; Ehrhardt T; Saul A Mol Biochem Parasitol; 1996 Nov; 82(2):167-80. PubMed ID: 8946383 [TBL] [Abstract][Full Text] [Related]
54. Plasmodium falciparum: gene structure and hydropathy profile of the major merozoite surface antigen (gp195) of the Uganda-Palo Alto isolate. Chang SP; Kramer KJ; Yamaga KM; Kato A; Case SE; Siddiqui WA Exp Parasitol; 1988 Oct; 67(1):1-11. PubMed ID: 3049134 [TBL] [Abstract][Full Text] [Related]
55. Expression of the merozoite surface protein gp195 in vaccinia virus. Sandhu JS; Kennedy JF Vaccine; 1994 Jan; 12(1):56-64. PubMed ID: 8303942 [TBL] [Abstract][Full Text] [Related]
57. Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine. Alving CR; Richards RL Immunol Lett; 1990 Aug; 25(1-3):275-9. PubMed ID: 2283158 [TBL] [Abstract][Full Text] [Related]
58. Potentiation of cell-mediated immune responses directed against P. falciparum sporozoite peptide vaccine by immunomodulators. Russo DM; Sundy JS; Maguire HC; Weidanz WP Adv Exp Med Biol; 1989; 251():203-7. PubMed ID: 2692427 [No Abstract] [Full Text] [Related]
59. Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity. Jones GL; Spencer L; Lord R; Mollard R; Pye D; Saul A Immunol Lett; 1990 Jul; 24(4):253-60. PubMed ID: 1697281 [TBL] [Abstract][Full Text] [Related]